Thanks to a managed access agreement with Bristol-Myers Squibb Co., of New York, the U.K.’s National Institute for Health and Care Excellence (NICE) announced that immunotherapy drug Opdivo (nivolumab) will be available within the Cancer Drugs Fund (CDF) for patients with head and neck cancer who have not responded to chemotherapy within six months and whose cancer has metastasized.